Highlights Harrow, Inc.

Equities

HROW

US4158581094

Market Closed - OTC Markets Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
10.94 ^USD	+4.29%		+7.36%	-2.32%

11/04	Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target	MT
22/03	B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Midday Decliners	20/03	MT
Harrow, Inc. Provides Earnings Guidance for the Year 2024	20/03	CI
Harrow Health Slumps 13% Premarket After Swinging to Core Net Loss in Q4 While Sales Jumped	20/03	MT
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03	CI
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03	CI
Restore stock falls as weak tech trading drags down annual results	14/03	AN
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	11/01	CI
Harrow, Inc. Partners with Leading Healthcare Market Access Technology Platforms	03/01	CI
Harrow Collaborating With Three Health Technology Platforms for US Launch of Vevye	03/01	MT
Harrow, Inc. Completes Transfer of the TRIESENCE New Drug Application	29/11	CI
Inflation Data Awaited as Exchange-Traded Funds, Equity Futures Edge Higher Pre-Bell Tuesday	14/11	MT
Harrow Health Q3 Core Loss Widens, Revenue Rises; Shares Plunge After Hours	14/11	MT
Harrow, Inc. Revises Revenue Guidance for the Full Year 2023	14/11	CI
Harrow, Inc. Provides Revenue Guidance for the First Quarter and Full Year 2024	14/11	CI
Harrow, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Harrow, Inc. Completes Transfer of Ndas and Launches FLAREX, Natacyn St, Verkazia, and ZERVIATE in the U.S	24/23/24	CI
Harrow Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Harrow Launches VIGAMOX in the U.S	31/23/31	CI
Bank Earnings Leave Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday	19/23/19	MT
Harrow Health Acquires Certain US, Canada Rights to Santen Pharmaceutical's Ophthalmic Portfolio	19/23/19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Harrow, Inc.

Equities

HROW

US4158581094

Highlights

Filters